MainStreet Investment Advisors LLC bought a new position in shares of Eli Lilly And Co (NYSE:LLY) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 5,023 shares of the company’s stock, valued at approximately $697,000.
A number of other large investors have also bought and sold shares of LLY. Pacitti Group Inc. acquired a new stake in Eli Lilly And Co during the 4th quarter worth approximately $25,000. Stonebridge Financial Planning Group LLC boosted its position in Eli Lilly And Co by 70.0% during the 1st quarter. Stonebridge Financial Planning Group LLC now owns 170 shares of the company’s stock worth $25,000 after buying an additional 70 shares during the period. Sugarloaf Wealth Management LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth approximately $26,000. Truvestments Capital LLC acquired a new stake in Eli Lilly And Co during the 1st quarter worth approximately $27,000. Finally, Solstein Capital LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 77.98% of the company’s stock.
Several research firms recently commented on LLY. Cowen lifted their target price on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Barclays assumed coverage on shares of Eli Lilly And Co in a research report on Thursday, February 27th. They set an “overweight” rating on the stock. Zacks Investment Research lowered their price target on shares of Eli Lilly And Co to $156.00 in a report on Wednesday, April 29th. Mizuho raised their price target on shares of Eli Lilly And Co from $148.00 to $155.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Finally, Cantor Fitzgerald raised their price target on shares of Eli Lilly And Co from $156.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, April 24th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $158.64.
Shares of NYSE:LLY traded down $1.12 during mid-day trading on Friday, hitting $151.16. The company had a trading volume of 2,322,495 shares, compared to its average volume of 2,875,585. The firm has a fifty day moving average price of $152.85 and a 200 day moving average price of $136.00. The company has a market capitalization of $145.65 billion, a PE ratio of 24.99, a price-to-earnings-growth ratio of 1.82 and a beta of 0.25. The company has a debt-to-equity ratio of 4.37, a current ratio of 1.11 and a quick ratio of 0.86. Eli Lilly And Co has a one year low of $101.36 and a one year high of $164.90.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Thursday, April 23rd. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.27. The company had revenue of $5.86 billion during the quarter, compared to analyst estimates of $5.48 billion. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. Eli Lilly And Co’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.33 EPS. Research analysts expect that Eli Lilly And Co will post 6.81 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $0.74 dividend. The ex-dividend date is Thursday, May 14th. This represents a $2.96 annualized dividend and a dividend yield of 1.96%. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.
In other Eli Lilly And Co news, SVP Aarti S. Shah sold 2,000 shares of the business’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $150.00, for a total transaction of $300,000.00. Following the completion of the sale, the senior vice president now owns 19,087 shares in the company, valued at approximately $2,863,050. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 230,000 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $145.42, for a total transaction of $33,446,600.00. Following the sale, the insider now owns 112,750,253 shares of the company’s stock, valued at approximately $16,396,141,791.26. The disclosure for this sale can be found here. Insiders sold a total of 906,320 shares of company stock valued at $132,984,238 in the last quarter. 0.09% of the stock is currently owned by company insiders.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.